Epigenetic modulation by small molecule compounds for neurodegenerative disorders
- 1 June 2018
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 132, 135-148
Abstract
No abstract availableKeywords
Funding Information
- Jawaharlal Nehru Centre for Advanced Scientific Research
- Department of Biotechnology, Department of Science and Technology, Government of India
- CEFIPRA
This publication has 185 references indexed in Scilit:
- Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseasesBrain Research Bulletin, 2013
- Long non-coding RNAs in Huntington's disease neurodegenerationNeurobiology of Disease, 2012
- MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunctionNeurobiology of Disease, 2012
- 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding siteEuropean Journal of Medicinal Chemistry, 2012
- Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse modelNeurobiology of Disease, 2011
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- The Basics of Brain DevelopmentNeuropsychology Review, 2010
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorChemistry & Biology, 2010
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injuryFree Radical Biology and Medicine, 2007